Primary Crystallization’s Influence on Fluticasone DPIs
Discover the impact of crystallization on mechanical properties & secondary processing of Fluticasone Propionate in dry powder inhaler formulations.
The influence of blend composition on the aerodynamic performance of a novel high resistance multi-dose device
Explore the study by Irene Rossi on blend composition’s influence on Aptar Prohaler®. Insights into FPM, MMAD, and aerodynamic performance in COPD treatment
Trade Marks Registration Certificate for Nanopharm Ltd
Discover Nanopharm’s leading role in pharmaceutical research, specializing in OINDP, nasal, and inhaled pharmaceutical solutions.
Challenging the Bioequivalence Hurdles for OINDPs: Achieving Q3 Structural Equivalence
Explore challenges in OINDP drug development, focusing on achieving bioequivalence in generic nasal formulations.
Characterizing Nasal Suspensions for Regulatory and Scientific Purposes
Explore Nanopharm’s in-depth research on particle size and its role in in vitro bioequivalence for nasal drug delivery. Discover how particle sizing impacts regulatory compliance and drug efficacy.
Effect of Device Design and Formulation on the In Vitro Comparability for Multi-Unit Dose Dry Powder Inhalers
Explore Nanopharm’s in-depth in vitro study on dry powder inhalers (DPIs). Learn how Computational Fluid Dynamics and Particle Size Distribution contribute to device performance and comparability.
Advanced microscopy techniques to assess solid-state properties of inhalation medicines
Unveil Nanopharm’s expertise in advanced microscopy for OINDP. Explore solid-state analysis and its impact on inhalation medicines, including dry powder inhalers.
